أحمد عبد العزيز

•Recognized as Best Achiever in both 2024 and 2025 with documented performance records, delivering 180% of target in 2024 and an exceptional 270% in 2025, reflecting consistent excellence and outstanding execution across the territory.
•Converted more than 400 healthcare professionals into active prescribers within just 6 months, building strong prescription habits and long-term brand loyalty across multiple specialties.
•Developed and maintained a powerful network of over 150 KOLs who became consistent brand advocates, driving sustained prescription growth across multiple therapeutic segments.
•Led, coached, and developed a field team of 5 Medical Representatives across 4 governorates, implementing CRM-driven territory planning and weekly performance reviews to ensure consistent execution and measurable results.

•Recognized as Best Achiever in 2020 and 2021 with documented performance records, delivering 124% in 2019, 180% in 2020, 227% in 2021, and 140% in 2022, demonstrating consistent high performance across four consecutive years in a highly competitive cardiovascular market.
•Positioned Artixiban as the market leader within just 12 months of launch, contributing directly to the products acquisition by Ramida for EGP 70 million, a landmark achievement that reflected the strength of market penetration and KOL engagement strategy executed across the territory.
•Launched and managed a diverse cardiovascular portfolio including Artixiban, Eli-Molivan, Cemicresto, and Lipifibrate, securing over 12, 000 units per month of Cemicresto 20 through strategic hospital tender accounts and long-term institutional relationships.
•Managed full tender cycles from negotiation through contract closure, building deep relationships with cardiologists, vascular surgeons, and orthopedic surgeons through behavioral profiling and consultative selling techniques.
•Built and maintained a strong network of KOLs and key institutional stakeholders across the Delta region, driving consistent portfolio growth and brand advocacy through structured scientific engagement and tailored account development plans.

•Recognized as Best Achiever in 2017 and 2018 with documented performance records, delivering 134% of target in 2017 and an outstanding 176% in 2018, driven by deep therapeutic knowledge and a highly consultative engagement approach.
•Founded the Mash Premiere Aesthetic and Dermatology KOL Club, a strategic scientific initiative that successfully united 40+ key opinion leaders across the Delta region, transforming them into consistent brand advocates and driving sustained long-term prescription growth across multiple dermatological and aesthetic product lines.
•Engaged KOLs through the MBO system with continuous performance monitoring via Solution Max, ensuring structured follow-up, measurable prescription tracking, and sustained brand loyalty across all targeted accounts.
•Successfully generated direct clinic orders and secured product listings within private hospital dermatology and aesthetic units, expanding market share and strengthening brand presence across the assigned territory through scientific detailing and relationship-driven selling.

•Recognized as Best Achiever in 2015 with documented performance records, delivering an exceptional 190% of target, with progressive and consistent growth of 132% in 2013, 148% in 2014, and 102% in 2016, reflecting a strong foundation in territory management and scientific detailing across a diverse therapeutic portfolio.
•Secured hospital tender contracts averaging 10, 000 to 17, 000 units per month of Famotin 20 and 40mg during 2014 and 2015, demonstrating strong institutional account management and negotiation skills at an early career stage.
•Built a powerful network of 200+ healthcare professionals across multiple specialties including gastroenterologists, general practitioners, and surgeons, driving consistent prescription growth and long-term brand loyalty across the territory.
•Promoted a comprehensive portfolio covering GIT, pain management, and anti-infective therapeutic areas including both oral and injectable product lines, delivering consistent market expansion and territory development results.

•Achieved 60% sales growth within the first year through rapid territory development and proactive HCP engagement, demonstrating strong commercial instincts and self-driven performance from the very beginning of a medical sales career.
•Promoted a focused orthopedic and OTC portfolio including Diclotazen, Gincostazen, and Rheumatizen Cream, building solid product knowledge and scientific detailing skills that formed the foundation of a consistently high-performing career.
•Built and maintained relationships with 120+ healthcare professionals including physicians and pharmacies across the territory, establishing early credibility and professional presence within the medical community.